 |
|
|
| |
Sofosbuvir + Ribavirin for 12 or 24 Weeks for Patients With HCV Genotype 2 or 3: the VALENCE Trial
|
| |
| |
Reported by Jules Levin
Presented at The Liver Meeting® 2013: 64th Annual Meeting of the American Association for the Study of Liver Diseases, November 1-5, 2013, Washington, DC
Stefan Zeuzem,1 Geoffrey M. Dusheiko,2 Riina Salupere,3 Alessandra Mangia,4 Robert Flisiak,5 Robert H. Hyland,6 Ari Illeperuma,6 Evguenia S. Svarovskaia,6
Diana M. Brainard,6 William T. Symonds,6 John G. McHutchison,6 Ola Weiland,7 Hendrik W. Reesink,8 Peter Ferenci,9 Christophe Hézode,10 Rafael Esteban11
1Johann Wolfgang Goethe University, Frankfurt, Germany; 2Royal Free and University College School of Medicine, Royal Free Hospital, London, United Kingdom; 3Tartu University Hospital, Tartu, Estonia; 4Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy; 5Medical University of Bialystok, Poland;
6Gilead Sciences, Inc., Foster City, CA; 7Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden; 8Academic Medical Center, Amsterdam, the Netherlands; 9Medical University of Vienna, Austria; 10Centre Hospitalier Universitaire Henri Mondor de Créteil, France; 11Hospital Universitario Vall d'Hebron, Barcelona, Spain
|
| |
|
|
|
|
|
